Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) issued its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.85) EPS for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Down 2.2 %
Titan Pharmaceuticals stock traded down $0.08 during midday trading on Thursday, hitting $3.58. The stock had a trading volume of 968 shares, compared to its average volume of 135,436. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The business has a fifty day moving average price of $3.60 and a 200 day moving average price of $4.09.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Titan Pharmaceuticals in a report on Monday. They issued a “sell” rating for the company.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- What is a Dividend King?
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- CD Calculator: Certificate of Deposit Calculator
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- How to trade using analyst ratings
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
